Antengene Initiates Phase I ERASER Study for ATG-017 in Combination with Nivolumab
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced the first patient dosing in...
Sichuan Huiyu Pharmaceutical’s KRAS G12C Drug HYP-2090PTSA Accepted for NMPA Review
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that the...
Puncture Robotic Secures $13.9 Million in Series A+ Funding to Advance Medical Robotics
Puncture Robotic, a Shanghai-based developer of medical robots, has reportedly raised RMB 100 million (USD...
Sanofi and AstraZeneca Receive FDA Approval for RSV Prevention Treatment Beyfortus
France-based Sanofi (NASDAQ: SNY) has announced that it, along with AstraZeneca (AZ; NASDAQ: AZN), has...
NMPA Releases 70th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 70th batch of reference drugs for...
Cutia Therapeutics’ CU-40101 Completes Phase I Clinical Trial for Androgenetic Alopecia
Cutia Therapeutics (HKG: 2487), a developer of dermatology therapies, has announced the completion of the...
Mabwell Bioscience’s 7MW3711 ADC for B7-H3 Gets Clinical Trial Approval in China
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced receiving clinical...
Bayer’s Kerendia Officially Launched in China for Type 2 Diabetes-Related CKD
German pharmaceutical giant Bayer’s (ETR: BAYN) Kerendia (finerenone), the first nonsteroidal, selective mineralocorticoid receptor (MR)...
Sensview Secures Tens of Millions in Series A+ Funding for X-Ray Detector Tech
Sensview, a developer of solid-state imaging chips and detector module products based in Chengdu, has...
Nanjing Enrui Kainuo Biotechnology Secures Pre-Series A Funding for Cell Therapy Development
Nanjing Enrui Kainuo Biotechnology Co., Ltd, a China-based cell therapy developer, has reportedly raised tens...
Shenzhen Salubris Pharmaceuticals Receives FDA Clearance for SAL0119 Clinical Trial
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, has announced that it...
Bio-Thera Solutions Receives NMPA Approval for CTLA-4 and PD-1 Inhibitor Combo Study
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that it has received approval from China’s...
Shanghai Pharmaceuticals Gets NMPA Green Light for Recombinant Human Adenovirus Type 5 Trial
Shanghai Pharmaceuticals (HKG: 2607; SHA: 601607), a leading pharmaceutical company in China, has announced that...
China’s NHC Issues Guidelines to Enhance Clinical Department Capacities for Serious Diseases
The National Health Commission (NHC) has issued a set of guidelines aimed at strengthening clinical...
Nanjing Immunophage Biotech’s IPG11406 Approved for SLE Clinical Trial in China
Nanjing Immunophage Biotech Co., Ltd, a China-based biotechnology company, has announced that it has received...
Pyrotech (Beijing) Biotechnology Secures $97.37 Million in Series A Financing
China-based biotech firm Pyrotech (Beijing) Biotechnology Co., Ltd announced the successful completion of a CNY...
Shanghai Henlius Biotech Announces Executive Leadership Changes
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced significant changes in its executive leadership....
Zai Lab and argenx Report Positive Preliminary Results from Vyvgart Hytrulo CIDP Study
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its Netherlands-based partner argenx SE (NASDAQ:...
ObsEva SA Regains Full Rights to Nolasiban After Terminating Yuyuan Biological License Deal
Swiss biopharmaceutical company ObsEva SA (SIX: OBSN) has announced that it has regained full rights...
Janssen’s Rybrevant Meets Primary Endpoint in Phase III NSCLC Study
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced positive results from...